0086 532 85065286 THOMASQIAO@KINGWISH.CN Qingdao, Shandong, China

Tylosin Tartrate

Home / Products / Tylosin Tartrate

Tylosin Tartrate molecular structure
Quick Facts
CAS Number1405-54-5
Molecular FormulaC46H77NO17
Molecular Weight916.112
PharmacopoeiaEP, CEP
Packaging25 KG/DRUM
GMP Certified CEP Certified

Product Story

Tylosin was discovered in the late 1950s by researchers at Eli Lilly and Company during a systematic soil-screening program. A soil sample collected in Thailand yielded a strain of Streptomyces fradiae (NRRL 2702) that produced a novel macrolide antibiotic with remarkable activity against Mycoplasma species — pathogens that were notoriously difficult to treat with existing antibiotics. Eli Lilly patented tylosin in 1960 (US Patent 2,965,547) and commercialized it under the brand name Tylan, which became one of the most important veterinary antibiotics of the 20th century. Tylosin is a 16-membered macrolide — structurally related to erythromycin (14-membered) but with a larger lactone ring that confers a distinct binding orientation at the 50S ribosomal subunit.

Tylosin's mechanism of action is bacteriostatic inhibition of bacterial protein synthesis. It binds to the 23S rRNA of the 50S ribosomal subunit, physically blocking the exit tunnel through which the growing polypeptide chain emerges, thereby arresting translation. Its spectrum covers the key respiratory and enteric pathogens in livestock: Mycoplasma gallisepticum and M. synoviae (chronic respiratory disease in poultry), Mycoplasma hyopneumoniae (enzootic pneumonia in swine), Brachyspira hyodysenteriae (swine dysentery), Clostridium perfringens (necrotic enteritis), and most Gram-positive bacteria. Notably, tylosin's coverage of spirochetes (Brachyspira species) distinguishes it from most other macrolides and makes it one of the few effective treatments for swine dysentery.

The two commercial salt forms — tylosin tartrate and tylosin phosphate — serve entirely separate routes of administration. Tylosin tartrate is the water-soluble salt, providing high aqueous solubility (>500 mg/mL) that enables administration via drinking water to entire poultry flocks or swine herds. This is critical in acute disease outbreaks, where individual animal injection is impractical and in-feed medication takes days to ramp up. Tylosin phosphate, in contrast, is virtually water-insoluble and is formulated exclusively as a feed additive premix for growth promotion and sub-therapeutic disease prevention. The two salts are not interchangeable — a poultry producer facing a CRD outbreak requires tartrate salt for water medication; a feed mill formulating a growth-promotion premix uses phosphate salt. The tartrate salt typically commands a premium price reflecting both its higher value proposition in acute treatment scenarios and the additional manufacturing complexity of the tartrate salt conversion.

As of mid-2026, the global tylosin market is valued at approximately USD 1 billion, driven by expanding poultry and swine production in Asia, Latin America, and Africa. China dominates tylosin API manufacturing, with production concentrated in Shandong, Ningxia, and Inner Mongolia. Market trends include tightening regulatory restrictions on macrolide antibiotics as growth promoters (EU ban, WHO AGP reduction guidelines) and rising demand in emerging markets where livestock production is intensifying. CEP certification confirms full compliance with EP monograph and European veterinary GMP standards. KingWish supplies CEP-certified tylosin tartrate supporting veterinary pharmaceutical manufacturers in regulated and emerging markets.

Quality Specifications

Potency (microbiological assay, dried basis)≥ 800 IU/mg, per EP monograph
Related Substances (HPLC)Tylosin A ≥ 80%; tylosin B ≤ 10%; tylosin C ≤ 7%; tylosin D ≤ 6%; any individual unspecified ≤ 3%
pH (2.5% aqueous solution)5.0 - 7.4
Water Content (Karl Fischer)≤ 4.5%
Residual SolventsCompliant with ICH Q3C; methanol ≤ 3,000 ppm
Regulatory FilingCEP (Certificate of Suitability, EDQM) — valid and active
GMP StatusManufactured under ICH Q7 GMP conditions, CEP confirmed

Veterinary Applications

Poultry — Drinking Water Medication

Chronic respiratory disease (CRD) from Mycoplasma gallisepticum/synoviae. Standard dosage: 0.5 g tylosin/L drinking water for 3-5 consecutive days. Also effective for necrotic enteritis (Clostridium perfringens). Mass medication advantage: entire flock treated simultaneously.

Swine — Swine Dysentery & Respiratory Disease

Swine dysentery (Brachyspira hyodysenteriae): 0.25 g/L drinking water for 3-10 days. Enzootic pneumonia (M. hyopneumoniae). Proliferative enteropathy (ileitis). Tylosin is one of few effective antibiotics against Brachyspira.

Additional Applications

  • Soluble powder formulations: Tylosin tartrate is used as the active ingredient in veterinary soluble powder products, either as a mono-component (Tylosin 50%/100% WSP) or in combination with other compatible APIs.
  • Injectable preparations: Tylosin base (from tartrate) reconstituted as tylosin 200 mg/mL injectable for cattle and swine. Intramuscular, 8-10 mg/kg body weight, 2-3 times daily.
  • Feed additive via premix: While phosphate salt is preferred for feed, tartrate can be formulated into feed premixes for strategic medication programs in some jurisdictions.

Sourcing Tylosin Tartrate: Key Checks

Documentation

Request CoA with microbiological potency (IU/mg, NOT just weight-based assay), HPLC chromatographic purity (tylosin A/B/C/D profile), pH of solution, water content (KF), residual solvents, and heavy metals. For EU/EEA, confirm active CEP status directly with the EDQM database. Verify the CEP covers the specific manufacturing site — site transfers without updated CEP are a compliance gap. Request batch-specific endotoxin data if the API is intended for injectable formulations.

Red Flags

Tylosin A below 80% with elevated B, C, or D components indicates fermentation process problems or product degradation. Potency reported only as "passes" without IU/mg value — especially suspicious for a fermentation product where batch-to-batch variability is inherent. CEP claims that cannot be verified on the EDQM database. Prices below the China FOB benchmark for CEP-certified material — tylosin tartrate commands a premium over phosphate, and non-CEP material should cost less.

Packaging & Logistics

Standard: 25 KG/DRUM with inner food-grade PE liner. Tylosin tartrate is hygroscopic — confirm air-tight seal and consider aluminium barrier bags for long-distance or tropical shipments. Store at controlled room temperature, protect from moisture. Standard lead time 4-8 weeks. Tylosin tartrate is relatively stable under proper storage (shelf life 3 years), but moisture ingress accelerates degradation and reduces potency.

Market Context

Global tylosin market valued at approximately USD 1 billion, growing modestly driven by poultry/swine production expansion in Asia and Africa. China accounts for dominant API production share. Key trend: EU ban on antibiotic growth promoters and WHO AGP reduction guidelines are shifting demand from phosphate (feed-grade) to tartrate (therapeutic-grade) as producers pivot from prevention to treatment. CEP certification is the key market-access differentiator. Market report

Frequently Asked Questions

Tylosin tartrate is water-soluble — it dissolves readily in water (>500 mg/mL) for administration via drinking water to poultry and swine. This makes it the form of choice for acute disease outbreaks (CRD, swine dysentery) requiring rapid whole-herd medication. Tylosin phosphate is water-insoluble and is used exclusively as a feed additive premix for growth promotion and disease prevention. The two salts are not interchangeable — they serve completely different routes of administration. The active moiety (tylosin free base) and antibacterial potency are equivalent; only the solubility and formulation route differ.
Tylosin was discovered by Eli Lilly researchers in the late 1950s from a Streptomyces fradiae strain isolated from Thai soil. Patented in 1960 and marketed as Tylan, it is a 16-membered macrolide that binds the 50S ribosomal subunit to block bacterial protein synthesis. Key targets: Mycoplasma gallisepticum/synoviae (poultry CRD), Mycoplasma hyopneumoniae (swine enzootic pneumonia), Brachyspira hyodysenteriae (swine dysentery — tylosin is one of few effective treatments), Clostridium perfringens (necrotic enteritis), and most Gram-positive bacteria including Staphylococcus and Streptococcus.
In poultry: chronic respiratory disease (CRD) caused by Mycoplasma gallisepticum and M. synoviae, at 0.5 g/L in drinking water for 3-5 days; also necrotic enteritis (C. perfringens). In swine: swine dysentery (Brachyspira hyodysenteriae) at 0.25 g/L for 3-10 days; mycoplasmal pneumonia (M. hyopneumoniae); proliferative enteropathy (ileitis, Lawsonia intracellularis). Tylosin can also be formulated as 200 mg/mL injectable for cattle and swine at 8-10 mg/kg IM, 2-3 times daily.
For EU/EEA markets, a Certificate of Suitability (CEP) from the EDQM is the most important regulatory document — it confirms the API meets the EP monograph and was manufactured under ICH Q7 GMP. KingWish holds a valid CEP for tylosin tartrate. Verify the CEP on the EDQM certification database. Additionally request: batch CoA with potency in IU/mg (NLT 800 IU/mg), HPLC purity profile (tylosin A/B/C/D), residual solvents (ICH Q3C), pH, and water content. For other regulated markets, confirm active VMF or DMF status. A supplier's willingness to share the CEP number for EDQM verification before an order is a key reliability indicator.
Standards: EP, CEP  |  CAS: 1405-54-5  |  Quality data verified against pharmacopoeia monograph COA and MSDS available  |  DrugBank  |  July 2026

Related Products